Literature DB >> 26405400

Perinatal Outcome in Idiopathic Polyhydramnios.

Meenakshi Lallar1, Rajesh Nandal2.   

Abstract

OBJECTIVES: To study perinatal outcome in idiopathic polyhydramnios.
METHODS: Case-control study was conducted in 500 pregnant women with idiopathic polyhydramnios (study group) and 500 normal pregnant women (control group) attending the outpatient department of SHKM Medical College, Haryana. Perinatal outcomes were recorded in both the groups.
RESULTS: Out of 500 cases with idiopathic polyhydramnios, maximum cases were diagnosed between 28 and 36 weeks of pregnancy (84.6 %), and maximum presented with mild polyhydramnios (82 %). In the study and control groups, there were no statistically significant differences in preeclampsia and gestational hypertension (p = 0.445 and p = 0.230). In the study and control groups, 74.6 and 79.6 % women, respectively, had normal vaginal delivery (p = 0.250). The study group recorded much higher number of preterm deliveries than the control group (54 %) (p = 0.000). In the study group, 51.8 % women had maternal complications, while in the control group, 13.6 % women had obstetrical complications. The study group recorded higher perinatal mortality (10.4 %) than the control group.
CONCLUSIONS: Idiopathic polyhydramnios is associated with higher perinatal morbidity and mortality than normal pregnancy.

Entities:  

Keywords:  AFI; Idiopathic; Perinatal; Polyhydramnios

Year:  2014        PMID: 26405400      PMCID: PMC4579156          DOI: 10.1007/s13224-014-0625-1

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  8 in total

1.  Idiopathic polyhydramnios and perinatal outcome.

Authors:  A Panting-Kemp; T Nguyen; E Chang; E Quillen; L Castro
Journal:  Am J Obstet Gynecol       Date:  1999-11       Impact factor: 8.661

Review 2.  A review of idiopathic hydramnios and pregnancy outcomes.

Authors:  Everett F Magann; Suneet P Chauhan; Dorota A Doherty; Monica A Lutgendorf; Marcia I Magann; John C Morrison
Journal:  Obstet Gynecol Surv       Date:  2007-12       Impact factor: 2.347

3.  Perinatal outcomes of idiopathic polyhydramnios.

Authors:  Salih Taskin; Emre Göksan Pabuccu; Ahkam Göksel Kanmaz; Korhan Kahraman; Gülay Kurtay
Journal:  Interv Med Appl Sci       Date:  2013-03-19

4.  Perinatal outcomes of polyhydramnios without associated congenital fetal anomalies after the gestational age of 20 weeks.

Authors:  Kuang-Chao Chen; Jui-Der Liou; Tai-Ho Hung; Dong-Ming Kuo; Jenn-Jeih Hsu; Ching-Chang Hsieh; Tsang-Tang Hsieh
Journal:  Chang Gung Med J       Date:  2005-04

5.  Idiopathic polyhydramnios and postnatal abnormalities.

Authors:  Harald Abele; Sandra Starz; Markus Hoopmann; Britta Yazdi; Katharina Rall; Karl Oliver Kagan
Journal:  Fetal Diagn Ther       Date:  2012-06-28       Impact factor: 2.587

6.  Maximal amniotic fluid index as a prognostic factor in pregnancies complicated by polyhydramnios.

Authors:  S Pri-Paz; N Khalek; K M Fuchs; L L Simpson
Journal:  Ultrasound Obstet Gynecol       Date:  2012-06       Impact factor: 7.299

7.  Hydramnios: anomaly prevalence and sonographic detection.

Authors:  Jodi S Dashe; Donald D McIntire; Ronald M Ramus; Rigoberto Santos-Ramos; Diane M Twickler
Journal:  Obstet Gynecol       Date:  2002-07       Impact factor: 7.661

8.  Idiopathic polyhydramnios and postnatal findings.

Authors:  Desirée M J Dorleijn; Titia E Cohen-Overbeek; Floris Groenendaal; Hein W Bruinse; Philip Stoutenbeek
Journal:  J Matern Fetal Neonatal Med       Date:  2009-04
  8 in total
  2 in total

1.  Comparing pregnancy, childbirth, and neonatal outcomes in women with idiopathic polyhydramnios: a prospective cohort study.

Authors:  Raziyeh Vanda; Mahnaz Bazrafkan; Maryam Rouhani; Fatemeh Bazarganipour
Journal:  BMC Pregnancy Childbirth       Date:  2022-05-11       Impact factor: 3.105

2.  miR‑199a‑3p suppresses cervical epithelial cell inflammation by inhibiting the HMGB1/TLR4/NF‑κB pathway in preterm birth.

Authors:  Juan Peng; Jiang Jiang; Huizi Wang; Xinzi Feng; Xudong Dong
Journal:  Mol Med Rep       Date:  2020-05-22       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.